Home » Stocks » Neon Therapeutics

Neon Therapeutics, Inc. (NTGN)

May 6, 2020 - NTGN was delisted (reason: acquired by BNTX)

Stock Price: $3.07 USD 0.00 (0.00%)

Updated May 6, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap	88.92M
Revenue (ttm)	n/a
Net Income (ttm)	-75.35M
Shares Out	28.96M
EPS (ttm)	-2.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	May 6, 2020
Last Price	$3.07
Previous Close	$3.07
Change ($)	0.00
Change (%)	0.00%
Day's Open	-
Day's Range	2.92 - 3.09
Day's Volume	3,609,767
52-Week Range	0.88 - 6.15

More Stats

Market Cap	88.92M
Enterprise Value	81.36M
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	28.96M
Float	n/a
EPS (basic)	-2.68
EPS (diluted)	-2.68
FCF / Share	-2.33

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	743,908
Short Ratio	1.29
Short % of Float	n/a
Beta	n/a

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	n/a
PB Ratio	6.16
Revenue	n/a
Operating Income	-76.22M
Net Income	-75.35M
Free Cash Flow	-66.60M

Net Cash	7.56M
Net Cash / Share	0.26
Gross Margin	n/a
Operating Margin	n/a
Profit Margin	n/a
FCF Margin	n/a
ROA	-70.63%
ROE	-156.16%
ROIC	-402.40%

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy	1
Overweight	0
Hold	2
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: Overweight

Price Target

$2.00*

Low

2.00

Current: $3.07

High

2.00

Target: 2.00

*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year	2019	2018	2017	2016
Revenue	-	-	-	-
Operating Income	-81.14	-78.70	-48.09	-27.42
Net Income	-79.78	-76.93	-47.54	-27.43
Shares Outstanding	27.88	15.04	1.69	0.99
Earnings Per Share	-2.86	-5.54	-34.32	-30.72
Operating Cash Flow	-73.41	-63.43	-41.28	-24.16
Capital Expenditures	-1.08	-3.22	-3.24	-2.36
Free Cash Flow	-74.50	-66.65	-44.52	-26.51
Cash & Equivalents	29.40	103	79.73	88.49
Total Debt	7.78	-	-	-
Net Cash / Debt	21.61	103	79.73	88.49
Assets	46.37	114	90.49	95.26
Liabilities	16.96	12.84	8.82	5.04
Book Value	29.42	101	-93.57	-38.49

Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name	Neon Therapeutics, Inc.
Country	United States
Employees	71

Stock Information

Ticker Symbol	NTGN
Stock Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NASDAQ: NTGN
IPO Date	June 27, 2018

Description

Neon Therapeutics, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial for the treatment of advanced or metastatic non-small cell lung cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of hormone-receptor-positive breast cancer, as well as NEO-STC-01, a neoantigen adoptive T cell therapy for the treatment of cancers driven or mediated by RAS mutations. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.